PopVax, a biotech startup in Hyderabad, will design and manufacture custom mRNA cancer vaccines, each built from a patient's own tumour data. Turnaround from tumour sequencing to a shippable vaccine is estimated at 8 to 10 weeks. The service, offered through its RNA Foundry, costs an estimated $300,000 (about Rs 2.7 crore) per patient, so it is mainly open to wealthy patients. It is experimental, not an approved treatment or a running trial, and PopVax currently has 100 patient slots.